Nasus Pharma (NSRX) investor relations material

Company overview and business model

• Clinical-stage specialty pharmaceutical company developing innovative intranasal powder-based products for acute medical conditions and public health threats.

• Lead product NS002 (Intranasal Epinephrine) targets anaphylaxis; NS001 (Intranasal Naloxone) development paused pending partnerships.

• Proprietary powder-based intranasal (PBI) technology aims for rapid, reliable drug absorption, with initial trials showing faster uptake than liquid-based solutions.

• Pipeline includes NS003 (Ondansetron for nausea/vomiting), NS004 (metabolic indication), and NS005 (cardiovascular indication), all in preclinical or early clinical stages.

• No FDA-approved products to date; additional clinical trials and regulatory approvals required for commercialization.

Financial performance and metrics

• As of June 30, 2026, accumulated deficit was $24.5 million, with no revenues from products.

• Cash, cash equivalents, restricted cash, and short-term deposits totaled $11.9 million; total shareholders' equity was $11.0 million.

• 11,710,808 Ordinary Shares outstanding as of June 30, 2026.

Use of proceeds and capital allocation

• Net proceeds from share sales intended for working capital and general corporate purposes; management has broad discretion over allocation.

• Pending use, proceeds may be invested in short-term, interest-bearing securities or U.S. government securities.